Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

How targeting a gene mutation could treat aggressive lung cancer

October 16, 2017 By Danielle Kirsh

MIT-Lung-Cancer-Target-01_0

In this image, lung cancer driven by the KRAS oncogene shows up in purple. MIT biologists have found a potential new way to treat this type of lung tumor, long thought to be “undruggable.” [Image from National Cancer Institute / Huntsman Cancer Institute at the Univ. of Utah]

Researchers at the Massachusetts Institute of Technology have found a gene mutation that could help treat an aggressive form of lung cancer that is known to be “undruggable.”

Gene mutations in the KEAP1 gene could help treat mutations in the KRAS gene that causes certain lung cancer types to be undruggable.

KEAP1 mutations occur with KRAS mutations in approximately 17% of lung cancer cases, according to the researchers. The researchers found that cancer cells that had KEAP1 genes want glutamine, which is used for protein synthesis and energy use. If the cells are deprived of glutamine, a treatment for KRAS and KEAP1 mutations may arise.

The researchers found that small-molecule-based inhibitors of glutaminase could slow cancer cell growth and resulted in smaller tumors in lung adenocarcinoma cell lines and tumors in mice who had KEAP1 mutations.

A study revealed a way to figure out which lung cancer patients would respond better to drugs that block glutaminase.

“All cell lines that we have currently tested that are KEAP1-mutant – independent of their KRAS status – appear to be exquisitely sensitive to glutaminase inhibitors,” Rodrigo Romero, first author on the paper, said in a press release.

Lung cancer is the leading cause of cancer death among men and women in the U.S. with about 155,870 deaths expected to happen in 2017. There is expected to be approximately 222,500 new lung cancer cases this year, according to the American Cancer Society.

Lung adenocarcinoma makes up about 40% of lung cancer cases. About 15% to 30% of those cases have a KRAS mutation. KRAS has been known to be hard to prevent, according to the researchers, because ways of blocking the KRAS protein interactions have been unsuccessful.

KRAS mutations usually have another mutation, which often includes KEAP1, the third most frequently mutated gene in lung adenocarcinoma. The researchers wanted to determine how the mutations affected lung cancer progression, so they created KEAP1 mutations in mice using a CRISPR/Cas9 gene editing system to target the gene.

CRISPR/Cas9 screenings showed that lung cancer cells that had KRAS and KEAP1 loss-of-function mutations needed increased amounts of glutamine more than other cells. Researchers tested two glutaminase inhibitors against the cancer cells to see if starving the mutations of glutamine could be a therapeutic vulnerability.

The researchers tested it against a cancer cell compound known as CB-839 that has been in phase I clinical trials for KRAS-mutant lung cancer. The test showed that CB-839 slowed the growth and the tumors were kept at a smaller size than normal in lung adenocarcinoma with KEAP1 mutation.

“There are also many clinical trials testing the efficacy of glutaminase inhibition in a variety of cancer types, independent of KRAS status. However, the results from these studies are still unclear,” Romero said.

KEAP1 protein usually stamps out NRF2, which controls the activation of an antioxidant response that helps remove toxins, reactive oxygen species from cells. The researchers disabled KEAP1 with loss-of-function mutations and saw that NRF2 proteins could come together and form a hyperactivation of the antioxidant response.

According to Romero, lung adenocarcinomas with the EAP1 mutation could use the hyperactivation to promote cellular growth or detoxify intracellular damaging agents.

Genes targeted by NRF2 had a greater expression in advanced stage IV tumors and patients who had up-regulated NRF2 tumors had worse survival rates.

The researchers plan to continue to study several mutations beyond KEAP1 that may work with KRAS in mice models.

“The complexity of human cancer can be quite daunting,” Tyler Jacks, director of MIT’s Koch Institute for Integrative Cancer Research and co-senior author of the study, said. ““The genetic tools that we have assembled allow us to create models of many individual subtypes of the disease and in this way begin to define the exploitable vulnerabilities of each. The observed sensitivity of KEAP1 mutant tumors to glutaminase inhibitors is an important example of this approach. There will be more.”

The research was published in the journal Nature Medicine and was funded by the Laura and Isaac Perlmutter Cancer Support Grant, the National Institutes of Health and the Koch Institute Support Grant from the National Cancer Institute.

(See the best minds in medtech live at DeviceTalks West, Dec. 11–12 in Orange County, Calif.)

Related Articles Read More >

DermaSensor skin cancer MedTech Innovator DeviceTalks Boston
DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
Product packaging for the Lucira combination COVID-19 and flu test
Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
gBETA Medtech accelerator picks its next startups
Hologic
Hologic handily beats the Street with Q2 results

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech